Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models

Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models

Abstract Background Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9-expressed cancer stem-like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy. A recent report revealed high levels of CD44v9-...

Full description

Bibliographic Details
Main Authors: Malinee Thanee, Sureerat Padthaisong, Manida Suksawat, Hasaya Dokduang, Jutarop Phetcharaburanin, Poramate Klanrit, Attapol Titapun, Nisana Namwat, Arporn Wangwiwatsin, Prakasit Sa-ngiamwibool, Narong Khuntikeo, Hideyuki Saya, Watcharin Loilome
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Cancer & Metabolism
Subjects:
Sulfasalazine
Cholangiocarcinoma therapy
CD44v9
Metabolic signature
Chemosensitivity
Online Access:https://doi.org/10.1186/s40170-021-00249-6

Internet

https://doi.org/10.1186/s40170-021-00249-6

Similar Items